Pharmaceutical companies that saw antitrust litigation against them revived by the U.S. Supreme Court last year are asking a federal judge in Atlanta to allow another them another shot at an appeal to keep so-called “pay-for-delay” deals alive.
After the seven-year-old antitrust case involving the maker of the male hormone booster AndroGel landed back in U.S. District Judge Thomas Thrash Jr.’s Atlanta courtroom, Thrash last month refused to do what he did in 2010—dismiss it. That prompted a renewed effort this month by the defendant pharmaceutical firms to appeal the case.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
